Sisäpiiritieto: Suominen Oyj:n ylimerkityn merkintäetuoikeusannin alustava tulos

Suominen suunnittelee ja toteuttaa merkintäoikeusannin, jossa yhtiö tarjosi enintään 77,1 milj. uutta osaketta; alustavien tulosten mukaan bruttotuotot ovat noin 28,0 milj. euroa ja anti oli ylimerkitty. Anissa merkittiin 81,5 milj. uutta osaketta (vastaa 105,6% uusista osakkeista) 0,36 euroon/osake, ja hallitus hyväksynnän jälkeen osakkeiden määrä noussee 58,26 milj. → 135,38 milj. osakkeeseen. Johto arvioi annin vauhdittavan Full Potential -ohjelmaa, ja uudet osakkeet alkavat arviolta kaupankäynnin 6.7.2026.

Analysis

The near-term market mechanism is technical, not fundamental: a heavily diluted post-rights register plus temporary-share trading usually creates pressure on the first few sessions after listing, even when the issue is oversubscribed. That matters because the equity story now depends less on solvency and more on whether incremental capital actually converts into higher throughput and better reliability fast enough to outrun the ~57% share-count expansion.

The main winner is the company’s survival profile; the main loser is per-share economics. Existing holders who did not fully participate effectively transferred value to new money if the turnaround stalls, while customers and suppliers gain a more stable counterparty but will likely keep pushing on price until execution improves. In nonwovens, that usually favors larger, better-capitalized peers in the sales process because procurement teams can play suppliers against each other; the dilution also lowers the odds of a distressed-sale spiral that would have dragged margins across the sector.

Catalyst path: days-to-weeks = technical post-issue supply and index/rebalancing flows; 1-3 months = proof on working capital, uptime, and gross margin; 6-18 months = whether the capital raise closes the valuation gap or simply resets a weaker base. The contrarian read is that the market may be overvaluing the oversubscription as a vote of confidence; much of that demand is likely forced or defensive from incumbents protecting pro rata ownership, not fresh conviction on ROIC. What would falsify a bullish stabilization view is any guidance that fails to show margin recovery by the next quarterly update or any sign the company still needs another balance-sheet fix before year-end.

Key Decisions for Investors

• Avoid chasing the first post-listing bounce in SUY1V; use any rally above the issue-adjusted level as a sell-the-rip setup until the new share float is fully absorbed and the company prints a cleaner quarterly gross-margin step-up.
• Set a 1-2 quarter watch on SUY1V for evidence that the capital raise is converting into operating leverage; if EBITDA margin and cash conversion do not improve meaningfully by the next results, treat the equity as a dilution trap rather than a turnaround.
• No direct trade in DNKEY or NRDBY: underwriting fees are too small to move bank earnings, so any long thesis in the syndicate banks would be noise relative to broader rates/credit exposure.
• For patient capital, consider a small exploratory long only on a sharp post-issue drawdown in SUY1V, with a hard stop if the stock cannot hold the rights-adjusted base once the temporary-share overhang clears; upside is a rerating away from distress, downside is renewed dilution risk.
• Use the next earnings release as the falsification point: if management does not show measurable improvement in reliability, utilization, and liquidity burn, exit any turnaround exposure immediately.